Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | CCR2 | P41597 | 18/20 | 0.55 |
| ▸ | CCR1 | P32246 | 1/20 | 0.48 |
| ▸ | CCR5 | P51681 | 1/20 | 0.48 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8365578 | 1.00 | HTT (0.58) | HTTCCR2CCR1CCR5CXCR4 | |
| SCHEMBL13766430 | 0.94 | HTT (0.51) | HTTCCR2CCR1CCR5CXCR4 | |
| SCHEMBL23374710 | 0.94 | HTT (0.51) | HTTCCR2CCR1CCR5CXCR4 | |
| SCHEMBL17152685 | 0.86 | — | — | |
| SCHEMBL17152686 | 0.86 | — | — | |
| SCHEMBL17152684 | 0.86 | — | — | |
| SCHEMBL10916213 | 0.86 | CCR2 (0.57) | HTTCCR2CCR1CCR5CXCR4 | |
| SCHEMBL7098870 | 0.83 | CCR2 (0.58) | HTTCCR2CCR1CCR5CXCR4 | |
| SCHEMBL8358035 | 0.82 | CCR2 (0.53) | HTTCCR2RAB9A | |
| SCHEMBL3008085 | 0.82 | CCR2 (0.53) | HTTCCR2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0294062-B1 | RESIN COMPOSITIONS AND MOLDED PRODUCTS THEREOF | UBE INDUSTRIES, LTD. (JP) | 1993-09-01 | — | — | EP | claimed |
| US-4879341-A | WATERPROOF, FLEXIBILE, RIDIGITY, | UBE INDUSTRIES, LTD. (JP) | 1989-11-07 | — | — | US | claimed |
| EP-1813616-B1 | Pyrazoloquinolines with immunomodulating activity | ACTIVE BIOTECH AB (SE) | 2013-03-27 | — | — | EP | disclosed |
| US-7557110-B2 | MAPKAP-K2; inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth; 5-[(trans-4-aminocyclohexyl)amino]-3-fluoro-6-methyl(pyrazolo[1,5-a]pyri- midin-7-yl)}(4-iodophenyl)amine | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| US-7354946-B2 | prominent growth inhibitory activity against tumor cells; cyclin dependent kinase inhibitors; colon cancer; N'-(3-t-butylisoindolino[3,2-b]oxazolidin-4-on-8-yl)-N-(4-(N-benzylpyrrolidin-3-yl)pyridin-2-yl)urea | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-04-08 | — | — | US | disclosed |
| US-7354946-B2 | prominent growth inhibitory activity against tumor cells; cyclin dependent kinase inhibitors; colon cancer; N'-(3-t-butylisoindolino[3,2-b]oxazolidin-4-on-8-yl)-N-(4-(N-benzylpyrrolidin-3-yl)pyridin-2-yl)urea | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-04-08 | — | — | US | disclosed |
| EP-1562944-B1 | PYRAZOLOQUINOLINES WITH IMMUNOMODULATING ACTIVITY | ACTIVE BIOTECH AB (SE) | 2007-02-14 | — | — | EP | disclosed |
| US-20070027147-A1 | Biarylurea derivatives | MSD K.K. (JP) | 2007-02-01 | — | — | US | disclosed |
| US-20070027147-A1 | Biarylurea derivatives | MSD K.K. (JP) | 2007-02-01 | — | — | US | disclosed |
| EP-0294062-B1 | RESIN COMPOSITIONS AND MOLDED PRODUCTS THEREOF | UBE INDUSTRIES, LTD. (JP) | 1993-09-01 | — | — | EP | disclosed |
| EP-0128775-B1 | RESINOUS COMPOSITION | TORAY INDUSTRIES, INC. (JP) | 1989-11-15 | — | — | EP | disclosed |
| US-4879341-A | WATERPROOF, FLEXIBILE, RIDIGITY, | UBE INDUSTRIES, LTD. (JP) | 1989-11-07 | — | — | US | disclosed |
| EP-0294062-A2 | Resin compositions and molded products thereof | UBE INDUSTRIES, LTD. (JP) | 1988-12-07 | — | — | EP | disclosed |
| US-4612346-A | BLEND OF POLYAMIDE AND MODIFIED POLYOLEFIN | TORAY INDUSTRIES, INC. (JP) | 1986-09-16 | — | — | US | disclosed |
| EP-0128775-A2 | Resinous composition | TORAY INDUSTRIES, INC. (JP) | 1984-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027147-A1 | Biarylurea derivatives | CDK6, CDK4, CCNI | HTT 3759/4885CCR2 1840/4885CCR1 2580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.